3 Biggest Risks for Bristol-Myers Squibb in 2017
Earnings more than doubled. Can the big drugmaker perform as well in 2017? Here are three of the biggest risks that Bristol-Myers Squibb faces in the new year.
from Biotech News
Earnings more than doubled. Can the big drugmaker perform as well in 2017? Here are three of the biggest risks that Bristol-Myers Squibb faces in the new year.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments